Dynamics of markers of lipid metabolism during combined preventive therapy of pregnant women with obesity and reduced vitamin D status

Authors

DOI:

https://doi.org/10.18370/2309-4117.2022.66.54-60

Keywords:

obesity, pregnancy, vitamin D, gestational endotheliopathy, leptin, resistin, adiponectin, Decristol

Abstract

Objectives: to evaluate the effectiveness of multidose supplementation of vitamin D on the dynamics of serum levels of markers of lipid metabolism in pregnant women with obesity.
Materials and methods. The study included 75 pregnant women with the І degree of obesity and low vitamin D status, who were divided into subgroups depending on the vitamin D dose of and the baseline 25(OH)D level in blood serum: I subgroup – 24 women with 25(OH)D less than 22.0 ng/ml who received Decristol 4000 IU/day; II subgroup – 26 pregnant women with 25(OH)D = 22.1–28.0 ng/ml who received Decristol 2000 IU/day; III subgroup – 25 patients with 25(OH)D over 28.1 ng/ml, who received 1000 IU of vitamin D per day. Pregnant women of all these subgroups also took acetylsalicylic acid at a dose of 100 mg/day. The control group included 26 practically healthy women who received 600 IU of vitamin D per day. Serum adipokinins levels were studied at 11–13, 22–24 and 31–33 weeks of gestation.
Results. Significant differences were found in the increase of leptin (p < 0.0001) and resistin (p < 0.0001) and the decrease of adiponectin (p = 0.006) in pregnant women with impaired vitamin D metabolism against the background of moderate obesity in the І trimester compared to the control group. A more positive effect was found for Decristol 4000 IU (patients with vitamin D deficiency), against the treatment of Decristol 2000 IU (patients with vitamin D deficiency). At 31–33 weeks of gestation, there was a statistically significant decrease in serum level of resistin (p = 0.006) and a similar increase in adiponectin (p = 0.025) in patients receiving vitamin D 4000 IU, compared with the same indicators in clinical subgroups. Resistin and adiponectin may be markers of perinatal pathology in obese pregnant women in the first trimester of gestation, in terms of specificity (91.5 and 78.7%, respectively), sensitivity (100.0 and 91.3%, respectively); positive probability (11.75 and 4.29%, respectively), negative prognostic value (100.0 and 94.9%, respectively) and test accuracy (94.3 and 82.9%, respectively).
Conclusions. The use of markers of lipid metabolism as diagnostic criteria during pregnancy in women with the І degree of obesity and low vitamin D status has predictor and prognostic value for the risk of perinatal pathology and helps to assess the effectiveness of comprehensive prophylactic therapy.

Author Biographies

O.V. Bulavenko, National Pirogov Memorial Medical University; Reproductive medicine clinic “Remedy-Vin”, Vinnytsia

MD, professor, head of Obstetrics and Gynecology Department No. 2;
Head of the reproductive medicine clinic

О.V. Bodnarchuk, National Pirogov Memorial Medical University, Vinnytsia

Graduate student, Obstetrics and Gynecology Department No. 2,

O.M. Honcharenko, National Pirogov Memorial Medical University, Vinnytsia

PhD, associate professor, Obstetrics and Gynecology Department No. 2

S.М. Kosianenko, National Pirogov Memorial Medical University, Vinnytsia

PhD, associate professor, Obstetrics and Gynecology Department No. 2

D.H. Konkov, National Pirogov Memorial Medical University, Vinnytsia

MD, professor, Obstetrics and Gynecology Department No. 1

References

  1. American College of Obstetricians and Gynecologists. “Obesity in Pregnancy: ACOG Practice Bulletin, Number 230.” Obstet Gynecol 137.6 (2021): e128-e144. DOI: 10.1097/AOG.0000000000004395
  2. Banjac, G., Ardalic, D., Mihajlovic, M., et al. “The role of resistin in early preeclampsia prediction.” Scand J Clin Lab Invest 81.6 (2021): 432–7. DOI: 10.1080/00365513.2021.1938205
  3. Berbets, A.M., Davydenko, I.S., Barbe, A.M., et al. “Melatonin 1A and 1B receptors’ expression decreases in the placenta of women with fetal growth restriction.” Reprod Sci 28.1 (2021): 197–206. DOI: 10.1007/s43032-020-00285-5
  4. Bulavenko, O.V., Tatarchuk, T.F., Konkov, D.G., Furman, O.V. “The modern strategies of clinical management of vitamin D deficiency in practices of the obstetrician gynecologist.” Reproductive Endocrinology 1.39 (2018): 38–44. DOI: 10.18370/2309-4117.2018.39.38-44
  5. Castro, N.P., Euclydes, V.V., Simões, F.A., et al. “The relationship between maternal plasma leptin and adiponectin concentrations and newborn adiposity.” Nutrients 9.3 (2017): 182. DOI: 10.3390/nu9030182
  6. Chaika, H.V., Konkov, D.G., Taran, O.A., Markevych, B.O. “Differences in anthropometric, somatotypological and components of body weight composition in teenager girls with primary dysmenorrhea.” Reproductive Endocrinology 1.57 (2021): 29–36. DOI: 10.18370/2309-4117.2021.57.29-36
  7. Cortelazzi, D., Corbetta, S., Ronzoni, S., et al. “Maternal and foetal resistin and adiponectin concentrations in normal and complicated pregnancies.” Clinical Endocrinology 66.3 (2007): 447–53. DOI: 10.1111/j.1365-2265.2007.02761.x
  8. D`Anna, R., Baviera, G., Corrado, F., et al. “Plasma adiponectin concentration in early pregnancy and subsequent risk of hypertensive disorders.” Obstet Gynecol 106.2 (2005): 340–4. DOI: 10.1097/01.aog.0000168441.79050.03
  9. Daskalakis, G., Bellos, I., Nikolakea, M., et al. “The role of serum adipokine levels in preeclampsia: A systematic review.” Metabolism 106 (2020): 154172. DOI: 10.1016/j.metabol.2020.154172
  10. Davis, E., Olson, C. “Obesity in pregnancy.” Prim Care 36.2 (2009): 341–56. DOI: 10.1016/j.pop.2009.01.005
  11. Denison, F.C., Aedla, N.R., Keag, O., et al. “Care of Women with Obesity in Pregnancy: Green-top Guideline No. 72.” BJOG 126.3 (2019): e62–e106. DOI: 10.1111/1471-0528.15386
  12. Duan, L., Han, L., Liu, Q., et al. “Effects of Vitamin D supplementation on general and central obesity: Results from 20 randomized controlled trials involving apparently healthy populations.” Ann Nutr Metab 76.3 (2020): 153–64. DOI: 10.1159/000507418
  13. Ehrhardt, C., Deibert, C., Flöck, A., et al. “Impact of diet quality during pregnancy on gestational weight gain and selected adipokines-results of a German Cross-Sectional Study.” Nutrients 14.7 (2022): 1515. DOI: 10.3390/nu14071515
  14. Fang, H., Judd, R.L. “Adiponectin regulation and function.” Compr Physiol 8.3 (2018): 1031–63. DOI: 10.1002/cphy.c170046
  15. Konkov, D., Belkania, G., Dilenyan, L., et al. Gestational endotheliopathy as trigger disorder of haemodynamics pregnancy supply. Preeclampsia. Ed. H. Abduljabbar. London: IntechOpen (2022). Available from: [https://www.intechopen.com/chapters/79595], last accessed Feb 17, 2022. DOI: 10.5772/intechopen.100737
  16. Goldstein, R.F., Abell, S.K., Ranasinha, S., et al. “Gestational weight gain across continents and ethnicity: systematic review and meta-analysis of maternal and infant outcomes in more than one million women.” BMC Med 16.1 (2018): 153. DOI: 10.1186/s12916-018-1128-1
  17. Kelly, A.C., Powell, T.L., Jansson, T. “Placental function in maternal obesity.” Clin Sci (Lond) 134.8 (2020): 961–84. DOI: 10.1042/CS20190266
  18. Kelly, C.B., Hookham, M.B., Yu, J.Y., et al. “Circulating adipokines are associated with pre-eclampsia in women with type 1 diabetes.” Diabetologia 60.12 (2017): 2514–24. DOI: 10.1007/s00125-017-4415-z
  19. Lara-Barea, A., Sánchez-Lechuga, B., Campos-Caro, A., et al. “Angiogenic imbalance and inflammatory biomarkers in the prediction of hypertension as well as obstetric and perinatal complications in women with gestational diabetes mellitus.” J Clin Med 11.6 (2022): 1514. DOI: 10.3390/jcm11061514
  20. Mallardo, M., Ferraro, S., Daniele, A., Nigro, E. “GDM-complicated pregnancies: focus on adipokines.” Mol Biol Rep 48.12 (2021): 8171–80. DOI: 10.1007/s11033-021-06785-0
  21. Mlyczyńska, E., Kieżun, M., Kurowska, P., et al. “New aspects of corpus luteum regulation in physiological and pathological conditions: involvement of adipokines and neuropeptides.” Cells 11.6 (2022): 957. DOI: 10.3390/cells11060957
  22. Mohana, C.A., Paul, S., Jahan, S., et al. “Serum leptin correlates with obesity but does not differ between gestational diabetes and normal glucose tolerance during 24–28 weeks of gestation.” Mymensingh Med J 31.2 (2022): 318–25.
  23. Münzberg, H., Morrison, C.D. “Structure, production and signaling of leptin.” Metabolism 64.1 (2015): 13–23. DOI: 10.1016/j.metabol.2014.09.010
  24. Nanda, S., Yu, C.K.H., Giurcaneanu, L., et al. “Maternal Serum Adiponectin at 11–13 Weeks of Gestation in Preeclampsia.” Fetal Diagnosis and Therapy 29.3 (2011): 208–15. DOI: 10.1159/000322402
  25. Ostafiichuk, S.O. “The role of resistin in the genesis of metabolic disorders in pathological pregnancy.” Ukr Biochem J 5.9 (2019): 55–62. DOI: 10.15407/ubj91.05.055
  26. Patenaude, J., Lacerte, G., Lacroix, M., et al. “Associations of maternal leptin with neonatal adiposity differ according to pregravid weight.” Neonatology 111.4 (2017): 344–52. DOI: 10.1159/000454756
  27. Pуrohova, V.I., Shurpyak, S.O., Oshurkevich, O.O., et al. “The role of vitamin D in maintaining women’s health and the modern principles of correction of the D-status.” Health of woman 9.135 (2018): 44–9. DOI: 10.15574/HW.2018.135.44
  28. Rao, S., Kumari, A., Sharma, M., Kabi, B.C. “Predicting maternal serum adiponectin and leptin level as biomarkers of pre-eclampsia: A prospective study.” J Obstet Gynaecol India 71.1 (2021): 58–65. DOI: 10.1007/s13224-020-01378-6
  29. Rasouli, N., Kern, P.A. “Adipocytokines and the metabolic complications of obesity.” J Clin Endocrinol Metab 93.11 (2008): s64–s73. DOI: 10.1210/jc.2008-1613
  30. Thagaard, I.N., Hedley, P.L., Holm, J.C., et al. “Leptin and Adiponectin as markers for preeclampsia in obese pregnant women, a cohort study.” Pregnancy Hypertens 15 (2019): 78–83. DOI: 10.1016/j.preghy.2018.12.002

Downloads

Published

2022-08-10

How to Cite

Bulavenko, O., Bodnarchuk О., Honcharenko, O., Kosianenko, S., & Konkov, D. (2022). Dynamics of markers of lipid metabolism during combined preventive therapy of pregnant women with obesity and reduced vitamin D status. REPRODUCTIVE ENDOCRINOLOGY, (66), 54–60. https://doi.org/10.18370/2309-4117.2022.66.54-60

Issue

No. 66 (2022)

Section

Pregnancy and childbirth

License

Copyright (c) 2022 О.В. Булавенко, О.В. Боднарчук, О.М. Гончаренко, С.М. Косьяненко, Д.Г. Коньков

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.